GSK buying Canada's ID Biomedical for $1.4 billion

09/8/2005 | Bloomberg

In a move to acquire a larger share of the flu vaccine market, GlaxoSmithKline is buying Canada's ID Biomedical in a $1.4 billion deal. GSK's Fluarix flu shot was approved by the U.S. FDA Aug. 31, but the company is expected to produce only 8 million doses this year, and one analyst suggests "capacity issues are what's driving" the move to buy the Canadian biotech firm.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN